Prometheus Bio Gets FDA Clearance of IND Application for 2nd Precision Program

 PRA052 is a monoclonal antibody blocking CD30 ligand that has a pleiotropic effect on both innate and adaptive immunity and targets a pathway that is distinct from TNF -

- PRA052 is the second clinical candidate identified using the Prometheus360™ platform with one of the strongest genetic associations to IBD and is linked to a broad range of immune-mediated diseases -

- Initiation of Phase 1 study of PRA052 expected in 4Q 2022 -

https://www.biospace.com/article/releases/prometheus-biosciences-receives-fda-clearance-of-ind-application-for-its-second-precision-program-pra052/